News | November 10, 2024
Vimta Labs reports Q2 FY25 PAT at Rs. 17 Cr
Q2 FY25 Total Income was at Rs. 85.4 crore
Q2 FY25 Total Income was at Rs. 85.4 crore
Hospital business revenues increase 13.9% to Rs. 1,655 crore
This product will be manufactured at Lupin’s Nagpur facility in India
_256_384.jpg)
Tyvek with Renewable Attribution is designed to help reduce the carbon footprint
Medanta is expected to incur a project capex of ~Rs. 600 crores in next 3-4 years
JB’s domestic business continued to out-perform the market with all our major brands posting strong growth
The group plans to establish new hospitals in Kerala developing large health cities in Kochi and Kozhikode
The company uses iPS cells to develop treatments for diseases relating to the kidney
US Generics grew 5% to Rs. 467 Crores for the quarter
Revenue growth was fueled by higher volumes and contributions from both existing and new centres
Subscribe To Our Newsletter & Stay Updated
